Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Purchased by Intrust Bank NA

Intrust Bank NA increased its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 6.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,823 shares of the company’s stock after purchasing an additional 183 shares during the quarter. Intrust Bank NA’s holdings in Axsome Therapeutics were worth $239,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. JPMorgan Chase & Co. increased its position in shares of Axsome Therapeutics by 14.9% in the third quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company’s stock valued at $19,062,000 after buying an additional 27,534 shares in the last quarter. Strategic Financial Concepts LLC purchased a new stake in Axsome Therapeutics in the 4th quarter worth $2,599,000. Intech Investment Management LLC raised its position in Axsome Therapeutics by 46.5% during the fourth quarter. Intech Investment Management LLC now owns 16,028 shares of the company’s stock worth $1,356,000 after acquiring an additional 5,087 shares during the period. Raymond James Financial Inc. purchased a new position in Axsome Therapeutics during the fourth quarter valued at $14,771,000. Finally, PDT Partners LLC purchased a new position in Axsome Therapeutics during the third quarter valued at $1,052,000. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Stock Down 2.7 %

NASDAQ:AXSM opened at $118.53 on Monday. Axsome Therapeutics, Inc. has a 52 week low of $64.11 and a 52 week high of $139.13. The stock’s fifty day moving average is $119.67 and its two-hundred day moving average is $101.22. The stock has a market capitalization of $5.78 billion, a price-to-earnings ratio of -19.79 and a beta of 1.00. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The firm had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million. Research analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Transactions at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now directly owns 42,187 shares in the company, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 22.40% of the company’s stock.

Wall Street Analyst Weigh In

AXSM has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Axsome Therapeutics in a research report on Tuesday, February 11th. They set a “buy” rating and a $176.00 price target for the company. Morgan Stanley increased their target price on Axsome Therapeutics from $125.00 to $190.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. Royal Bank of Canada lifted their price target on Axsome Therapeutics from $143.00 to $192.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 19th. HC Wainwright reiterated a “buy” rating and set a $200.00 price target on shares of Axsome Therapeutics in a research report on Thursday, March 6th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $153.00 price objective on shares of Axsome Therapeutics in a report on Wednesday, February 19th. One analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $167.64.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.